Development of a TLR9 Inhibitor for Cerebral Malaria

Partnership Objective

Development of a new treatment for cerebral malaria.

Given the widespread prevalence of malaria and the resistance observed with available drugs, the availability of newer agents for its treatment is extremely urgent. Given the widespread prevalence of malaria and the resistance observed with available drugs, the availability of newer agents for its treatment is extremely urgent. Copyright IFPMA

What are the health needs and challenges?

Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. It is estimated that in 2012, malaria caused over 627,000 deaths, mostly among African children. Cerebral malaria occurs in approximately 10% of malaria cases and is associated with a 25-50% mortality within 24-48 hours.

Chloroquine, an agent used in the treatment of malaria for several decades has become less effective, and in some areas chloroquine resistant parasites have climbed to 90% of cases. Resistance to the newer agent artemisinin has also been described. Given the widespread prevalence of malaria and the resistance observed with available drugs, the availability of newer agents for its treatment is extremely urgent.

Description of partnership activities and how they address needs and challenges

Eisai’s ER-820446 is a promising compound for the treatment of cerebral malaria. A selective inhibitor of Toll Like Receptor 9 (TLR9) signaling, ER-820446 has in some models significantly reducedmortality due to cerebral malaria. Pre-clinical development activities have been initiated in conjunction with researchers at the Oswaldo Cruz Foundation in Brazil and the University of Massachusetts in the USA.

The partnership frequently reviews the progress of the research and considers options for addressing any challenges.

Partnership information

Company(ies) Eisai

Partner(s) Federal University of Minas Gerais, Fundação Oswaldo Cruz (Fiocruz), University of Massachusetts

Type of Partner(s) Academia / Hospitals, NGOs

Therapeutic Focus Infectious Diseases

Disease(s) Malaria

Program Type(s) Research & Development - Development of Treatments

Targeted Population(s) Children, Mothers, Patients in needs of treatment, People with low income, Women

Region(s) Latin America & Caribbean, Sub-Saharan Africa

Number of Countries 49

Country(ies) Angola, Benin, Botswana, Brazil, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Research Country(ies) Brazil, United States of America

Start Date 2006

More information Eisai Access to Medicines

Anticipated completion date Ongoing